北京赛科希德科技股份有限公司2025 年半年度报告 公司代码：688338 公司简称：赛科希德 北京赛科希德科技股份有限公司 北京赛科希德科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述在经营过程中可能面临的各种风险，请查阅本报告"第三节管理 层讨论与分析"之"四、风险因素"，敬请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人吴仕明、主管会计工作负责人李国及会计机构负责人（会计主管人员）郭丽声 明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请 投资者注意投资风险。 九、 是否存在被控股股东 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Saikohide, a company in the medical device industry, which has a current stock price of 27.8 yuan and a market capitalization of 2.951 billion yuan [1] - Saikohide's rolling price-to-earnings (PE) ratio is 27.92, significantly lower than the industry average of 56.58 and the median of 39.97, indicating a relatively undervalued position within its sector [1][2] - The company has seen an increase in shareholder numbers, with 6,725 shareholders as of March 31, 2025, up by 1,118 from the previous count, and an average holding value of 352,800 yuan per shareholder [1] Group 2 - Saikohide specializes in the research, development, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis [1] - The company’s main products include automated testing devices, coagulation analyzers, blood rheology analyzers, and various coagulation and blood rheology reagents and consumables [1] - In the latest quarterly report for Q1 2025, Saikohide reported a revenue of 68.6393 million yuan, a year-on-year decrease of 9.47%, and a net profit of 23.1329 million yuan, down 23.98%, with a gross margin of 62.49% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Saikohide, a company specializing in medical devices for thrombosis and hemostasis diagnostics [1][2] - As of August 4, Saikohide's closing price was 27.48 yuan, with a rolling price-to-earnings (PE) ratio of 27.59 times and a total market capitalization of 2.917 billion yuan [1] - The average PE ratio for the medical device industry is 54.32 times, with a median of 38.11 times, positioning Saikohide at the 54th rank within the industry [1][2] Group 2 - As of March 31, 2025, Saikohide had 6,725 shareholders, an increase of 1,118 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company's main business includes the research, development, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis [1] - In the latest quarterly report for Q1 2025, Saikohide reported revenue of 68.6393 million yuan, a year-on-year decrease of 9.47%, and a net profit of 23.1329 million yuan, down 23.98%, with a gross profit margin of 62.49% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Saikohide, a company in the medical device industry, which is currently facing a decline in revenue and profit [1][2] - As of July 8, Saikohide's stock closed at 25.31 yuan, with a rolling PE ratio of 25.42, marking a new low in 64 days, and a total market capitalization of 2.686 billion yuan [1] - The average PE ratio for the medical device industry is 51.58, with a median of 37.46, positioning Saikohide at 55th place among its peers [1][2] Group 2 - Saikohide's main business focuses on the development, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis [1] - The latest quarterly report for Q1 2025 shows that the company achieved revenue of 68.6393 million yuan, a year-on-year decrease of 9.47%, and a net profit of 23.1329 million yuan, down 23.98%, with a gross profit margin of 62.49% [1] - As of March 31, 2025, Saikohide had 6,725 shareholders, an increase of 1,118 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]